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Application of Genome-Wide Single
Nucleotide Polymorphism Typing:
Simple Association and Beyond




he International HapMap Project and the arrival of
technologies that type more than 100,000 SNPs in a
single experiment have made genome-wide single
nucleotide polymorphism (GW-SNP) assay a realistic
endeavor. This has sparked considerable debate regarding the
promise of GW-SNP typing to identify genetic association in
disease. As has already been shown, this approach has the
potential to localize common genetic variation underlying
disease risk. The data provided from this technology also
lends itself to several other lines of investigation; autozygosity
mapping in consanguineous families and outbred
populations, direct detection of structural variation,
admixture analysis, and other population genetic approaches.
In this review we will discuss the potential uses and practical
application of GW-SNP typing including those above and
beyond simple association testing.
Introduction
The ﬁrst steps toward effective whole genome association
experiments were taken with the inception and completion
of stages I and II of the International HapMap Project (http://
www.hapmap.org; [1,2]). This project aimed to produce a
minimal set of informative single nucleotide polymorphisms
(SNPs) to tag variation throughout the genome [3]. In an
effort to understand how the requirements for SNP tagging
approaches may vary from population to population,
HapMap data was initially generated in four discrete
populations: Yoruba from Ibadan, Nigeria (YRI); Japanese in
Tokyo, Japan (JPT); Han Chinese in Beijing, China (CHB); and
Utah, United States, residents with ancestry from northern
and western Europe (CEU).
A key effort undertaken in parallel with the HapMap
Project involved the production of cost-effective methods to
perform high-throughput genotyping accurately and
reproducibly. There are two prominent companies offering
high-throughput genome-wide (GW) genotyping that can be
applied within an end user’s laboratory: Affymetrix and
Illumina. The combination of these technological and
informatic advances now make GW-SNP genotyping a
realistic possibility for well-funded laboratories; the likely
decrease in cost that will occur over the next ﬁve years
suggests that this technology will become a standard
technique in molecular genetic and clinical diagnostic
laboratories. In this review article we will discuss the potential
applications and practical considerations of GW-SNP assay.
While we have experience in dealing with large datasets (;.5
billion genotypes) from both Affymetrix and Illumina
technologies, much of this article focuses on the output and
metrics produced using the Illumina Inﬁnium assays, because
our primary in-house work has centered on this platform.
However, many of the concepts and applications discussed
here are applicable to data derived from other platforms.
Genome-Wide Association
GW-SNP assays have been anticipated as a tool for the
dissection of disease risk factors for many years [4]. Much of
the discussion surrounding the application of GW-SNP assays
has centered on the utility of this method in identifying
common genetic variability that underlies disease [5,6]. This
discussion has focused on the relative power of these types of
study and the potential problems and pitfalls associated with
this approach, resulting in numerous review and opinion
pieces. For the sake of brevity we will not discuss these
considerations in detail. Brieﬂy, however, the primary
concern before undertaking a genome-wide association
experiment is one of statistical power to observe an effect of a
speciﬁc size. To date this issue has largely been addressed by
prospective power calculations using simulation. These
analyses generally rely on parameters such as the model of
disease risk (dominant, recessive, additive) and estimates of
the presence and magnitude of genetic and allelic
heterogeneity; in reality the extent of genetic inﬂuence and
genetic mode of action for individual loci within most
diseases is unknown, and most of these approaches do not
consider the confound of population stratiﬁcation [7,8], thus
these predictions are essentially ‘‘best-guess’’ estimates.
Highlighting the approximate nature of these calculations,
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controls appears to have been adopted as the realistic
standard for complex diseases. Compared with most genetic
case control studies, which typically number a few hundred
cases and controls, 1,000 samples in each cohort is relatively
large; however, it is doubtful that even sample series of this
size will provide sufﬁcient power to identify recessive loci and
less likely that the identiﬁcation of gene–gene or gene–
environment interactions will be tenable. Nevertheless, this
size of study appears to be an achievable goal, although
currently only for consortia or particularly well-funded
laboratories. The considerable cost of these experiments
coupled with the potential promise of this approach has led
funding agencies to encourage sharing of resources to
perform these assays, including both sharing of DNA samples
and public release of genotype data. Implicitly, this policy
highlights a strength of GW-SNP experiments, i.e., genotype
data are essentially digital and additive; thus experiments on
the same platform can be easily compared or combined to
increase power and sensitivity. The public release of genotype
data inevitably raises issues with respect to patient privacy
and appropriate clinical research protocols and consenting
procedures. While these restrictions may preclude use of
some existing collections for publicly funded experiments,
with adequate foresight these issues are not insurmountable.
Indeed initiatives such as the Genetic Association
Information Network (http://www.fnih.org/GAIN/
GAIN_home.shtml) and the Wellcome Trust Case Control
Consortium (http://www.wtccc.org.uk) will release genotype
data, albeit with varying restrictions on who can access the
data.
Another consideration in the design of GW-SNP
experiments is the choice of source tissue; although the
amount of DNA required is relatively small, the experiments
are exquisitely sensitive to DNA quality. Consequently,
quality of the sample source material may be as important as
concerns over study design and sample size. Many large-scale
experiments, particularly those publicly funded, will be
performed on samples from public open-access repositories,
indeed these resources were set up in anticipation of GW-
SNP and other high-throughput methodologies. Repositories
have commonly used Epstein-Barr virus immortalization to
create lymphoblast cell lines (LCLs) primarily to provide a
renewable source of high-quality genetic material. An
understandable concern is the ﬁdelity of the genomic DNA in
these cultured cells when compared with that from the source
tissue. Experiments within our laboratory suggest that
genomic DNA from LCLs produces GW-SNP data that is
relatively faithful to that derived from the blood samples used
to create the LCLs; the LCL creation and passage process
results in alterations in less than 0.1% genotype calls when
compared directly with the source tissue. In terms of genome-
wide association, such a small and apparently randomly
distributed alteration is unlikely to confound results. An
additional and increasingly popular method for generating
large amounts of genomic DNA is genome-wide ampliﬁcation
(GWA). This technique allows the production of signiﬁcant
amounts of genomic DNA from a variety of sources, including
archived ﬁxed tissue. This approach is of obvious utility,
particularly where samples are rare or are individual ﬁxed
samples of particular importance. There is currently limited
data on the use of this technology in the creation of starting
material for GW-SNP assay; however, experiments assessing
this approach in high-plex assays of .2,000 SNPs show a high
degree of genotype concordance between ampliﬁed and
source material [9]. While these data suggest that GWA will be
a viable approach to generate material for GW-SNP assay, it is
clear that the initial template must be good quality high
molecular weight DNA; the potential for failed genotypes or
allelic bias as a result of ampliﬁcation artifacts or
contamination is likely to be inversely related to sample
quality.
Although GW-SNP assays have only been available for a
short period, several studies using this approach have already
been published [10–12]. One such study resulted in the
discovery of variability within CFH (complement factor H) as
a strong risk factor for age-related macular degeneration [11].
This work used a relatively small number of SNPs
(approximately 100,000) in a small cohort of 96 cases and 50
controls. The primary data showed strong association at two
SNPs within CFH; resequencing revealed the presence of a
coding alteration in CFH associated with a 7-fold increase in
risk of disease for homozygous carriers. Not only did this
study highlight the utility of GW-SNP assay but it also showed
that relatively small case-control series can provide valuable
information.
Perhaps as important as deﬁning a positive signal, GW-SNP
association studies may also deﬁne the limits of inﬂuence of
common genetic variability in a particular disorder. One can,
in the absence of the requisite signiﬁcant signal, show that
there is no common variant that confers a risk stronger than
a predetermined odds ratio in the population studied. Put
simply, in a perfectly designed experiment this approach has
the power not only to tell you what is there, but also to tell
you what is not there. Of course in the real world where likely
confounds such as population stratiﬁcation and incomplete
genomic coverage [13,14] lead to suboptimal experimental
design, the absence of evidence is not necessarily evidence of
absence, and of course the results from a single experiment
are only directly relevant to the population studied. However,
genomic coverage is increasing, genomic control or principal
component analysis [15] may reduce stratiﬁcation, and our
understanding of interpopulation genetic heterogeneity over
the next decade is likely to improve. Thus while these
experiments are unlikely to unequivocally rule out the
presence of other simple genetic inﬂuences in a particular
trait, they do provide a reasonable reference point with which
we can make estimates of the presence/absence of loci. This
has particular relevance for funding agencies and scientists
alike; it tells us when we should stop looking for a common
genetic variant at a certain power.
Considerations for Data Handling and Analysis
As the density of GW-SNP genotyping platforms continues
to increase, it is plausible that many laboratories will attempt
to manage billions of genotypes per year. Whether
laboratories are producing these genotypes directly, through
collaborations, or retrieving them from a public resource
(http://www.ncbi.nlm.nih.gov/WGA), the challenge of data
volume still remains.
An obvious choice for data management is to use a
relational database, which offers many levels of storage
(including backup) and access (with privileges) to the data.
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mundane but important jobs fairly easy, and facilitates the
ability to use the data in many different forms, such as
exporting for multiple analysis formats. An issue speciﬁc to
the storage of SNP genotypes, which may affect which
encoding is used to store a genotype and its sample and
marker relationship, is that they have a direction and
orientation; this latter point is of particular importance as
even within platforms a SNP’s encoded orientation may
change between product releases. Because of the storage
requirements (each chip image may be 2 Gb in size), typically
chip images and other chip artifacts will be archived with a
low level of access or discarded once genotypes have been
called; however, as noted below many researchers will have
interest in data above and beyond genotypes, wishing to
access metrics that provide information on copy number.
Thus investigators should expect to store relevant metrics in
addition to the raw genotypes.
Available tools for data management and analysis of GW-
SNP data are currently scarce; however, a few exist or are
under development, such as GERON Genotyping (http://
neurogenetics.nia.nih.gov), Snpgwa (personal communication
Drs. Langfeld and Steigert, Wake Forest University), and
PLINK (http://pngu.mgh.harvard.edu/;purcell/plink). These
new tools should perform whole genome association analysis
quickly; especially when compute clusters are available for
parallel execution. Analyses within Snpgwa and PLINK
include tests for allelic, genotypic, dominant, recessive, and
additive model associations as well as tests for linkage
disequilibrium and Hardy-Weinberg equilibrium. These tools
also allow testing of haplotype association in consecutive
(Snpgwa) or selected (PLINK) markers. Association analysis
with permutations and multiple testing corrections are
available, but these steps may add considerably to
computational time. An underestimated and as yet unsolved
problem with GW-SNP data is that of data visualization,
particularly integration of results with current genomic data.
Some of these tools will be made available under an open-
DOI: 10.1371/journal.pgen.0020150.g001
Figure 1. Multiple Regions of Extended Homozygosity within a Single Subject Born from a First Cousin Marriage
The regions of extended homozygosity on Chromosomes 3 (upper panel) and 18 (lower panel) are outlined in red. Homozygosity is shown by a lack of
A/B genotype calls (corresponding to a B allele frequency of 0.5) coupled with a normal copy number, indicated by an average log R ratio of 0.
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much the same way that sharing the resulting GW-SNP data
should have an additive effect for the advancement of
biological understanding, this should apply to the software
tools as well. While sharing these toolsets alone may be
sufﬁcient for repeatable analysis and data handling, doing so
under on open-source license has additional beneﬁts. The
open-source model lends itself well to the formation of a
collaborative community in the development, extension, and
use of software; additionally this adds to the diversity of
functionality, speed with which changes may be made, and
scrutiny of the correctness and efﬁciency of implemented
algorithms.
Homozygosity Mapping in Disease
Perhaps the most obvious application of this technology
outside of allelic, haplotypic, and genotypic association
testing is in the detection of tracts of extended homozygosity,
particularly those believed to contain a genetic lesion
underlying disease. While the concept of autozygosity
mapping was ﬁrst proposed in 1987 [16], the advent of GW-
SNP assay offers many advantages over previous methods
aimed to deﬁne recessive loci. In kindred with an apparently
recessive disorder, particularly one where parental
consanguinity is suspected, this approach can be used to map
regions of extended homozygosity with high resolution and
essentially complete genomic coverage. These assays can be
completed in a short amount of time; typically GW-SNP assay
of a family of fewer than 50 individuals takes less than a week.
The data lends itself to immediate visualization of large
homozygous tracts (Figure 1). Because all tracts of disease
segregating homozygosity will be identiﬁed and all
heterozygous regions/nonsegregating homozygous tracts
excluded, one can be conﬁdent that the region harboring the
genetic lesion underlying disease has been identiﬁed; thus,
with the caveat that the model needs to be correct (i.e., the
disease must be caused by a homozygous change inherited
from a relatively recent common ancestor), generation of lod
scores for these types of analysis is effectively redundant.
Whether this technique will identify single or multiple
regions of interest and the size of these regions relies on
several factors; the degree of parental consanguinity, the
number of informative family members, and the relatively
stochastic nature of recombination. In small families where
there are fewer meioses and thus more chance for variation
in the length and number of homozygous tracts, power
calculation for these types of experiments will generally be
uninformative.
In families where affected family members exhibit a low
level of inbreeding, or where there is a high degree of
separation between affected family members, the size of a
potential disease-segregating region is likely to be small. In
this event the high level of resolution provided by GW-SNP
assay offers a great advantage over traditional genome-wide
linkage scans.
The family-based work logically leads to another
application, that this methodology may be used to perform
autozygosity mapping for disease in populations of
individuals with unknown pedigree structures [17]. This
suggests the possibility of performing autozygosity mapping
in cohorts ranging from relatively conserved populations to
those believed to be ostensibly outbred. Data from our
laboratory has shown a surprisingly high level of apparent
DOI: 10.1371/journal.pgen.0020150.g002
Figure 2. Log R Ratio and B Allele plots for Two Samples Showing Genomic Duplication
Genomic duplication is indicated by an increase in log R ratio and B allele frequency clusters outside of the expected values of 1 (B/B), 0.5 (A/B), and 0
(A/A).
(A) Shows duplication of a small segment on Chromosome 1 (red arrow).
(B) Shows duplication of a region of approximately 7 Mb on Chromosome 21, outlined in red. This region contains APP, and the duplication mutation
results in a neurodegenerative phenotype (courtesy of J. Hardy).
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of sampled individuals possessing tracts of homozygous
genotypes larger than 5 Mb (unpublished data), and these
observations are consistent with analyses of HapMap data
[18]. One could expect therefore that this methodology may
be applied to localize homozygous genetic mutations
underlying disease. In addition to speed and resolution, GW-
SNP assay offers one more advantage in autozygosity
mapping: this technique allows the direct visualization of
structural genetic mutation such as genomic deletion and
duplication, which often underlie recessive disorders.
Direct Detection of Structural Variability
Two primary metrics produced by the Illumina Inﬁnium
technology allow the direct visualization of structural
genomic variability, B allele frequency, and normalized R.
Because there is considerable redundancy at each locus
interrogated, both alleles of each SNP are assayed multiple
times; accordingly, B allele value for an individual SNP in a
single sample gives an estimate of the proportion of times an
individual allele at each polymorphism was called A or B. This
metric is simply viewed as B allele frequency, thus an
individual homozygous for the B allele would have a score
close to 1, an individual homozygous for the A allele a score
close to 0, and a score of approximately 0.5 would indicate a
heterozygous A/B genotype. Deviations away from these three
cluster positions are indicative of a deviation from a simple
diplotype. R is a measure of the signal intensity for a locus,
and thus when compared with an average expected value for
that locus, the resulting log R ratio provides an indirect
measure of copy number. A signal in the test sample which is
stronger than the expected signal is indicated by a log R ratio
above one and indicates a copy number increase; conversely a
weaker signal than that expected for an individual SNP
results in a decreased log R ratio and is suggestive of a
deletion.
Visualization of B allele frequency and log R ratio can be
used to identify genomic copy number variation in individual
samples (Figure 2). Currently, analysis of these data needs to
be performed manually. This coupled with the fact that there
is a small amount of interassay variation in the metrics B
allele frequency and R at individual loci means that
identifying copy number variations affecting a single SNP or
a small number of SNPs is challenging; however, copy number
variation affecting ten or more contiguous SNPs is relatively
easy to detect. Thus the resolution of this technique is
sensitive to SNP density of the assay at any particular
genomic locus. For all platforms this varies throughout the
genome. However, typically we observe copy number
variations as small as 200 kb using the Inﬁnium I assays
(109,365 SNPs) and as small as 50 kb using the Inﬁnium II
assays (317,511 SNPs).
The ability to view and score structural genomic variation
DOI: 10.1371/journal.pgen.0020150.g003
Figure 3. GW-SNP Assay Using the Illumina Infinium II Arrays Reveals Structural Variation in Chromosomes
(A) Common laboratory cell line HEK293.
(B) Common laboratory cell line M17.
(C) Human embryonic stem cell line 293F7.
(D) Human embryonic stem cell line Bg01P3SFF2.
These include apparent multiplication and deletion mutations in the M17 and HEK293 lines, multiplication mutations across line 293F7, and duplication
Chromosome 17 in line Bg01P3SFF2.
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analysis of copy number polymorphisms as disease risk alleles
in GW-SNP association experiments. Given the biological
plausibility of a role for altered gene dose/expression in
disease, this is of particular interest. This assay also lends
itself to the detection of structural mutation underlying
monogenic disease; within our laboratory we have detected
deletion and duplication of PRKN in addition to
multiplication mutations across SNCA and APP (unpublished
data; Figure 2).
This assay may also be used to assess the role and extent of
somatic structural mutation, an application that is
immediately applicable to cancer but conceivably may be
used to assess this phenomenon in other disorders. While
analysis of copy number variation has been performed
previously using custom clone or oligonucleotide arrays for
comparative genomic hybridization, these products have
often provided limited coverage in a format that is either not
reproducible or not easily transferable between laboratories.
The availability of a transferable technology that can provide
similar results in a highly reproducible manner is a signiﬁcant
step toward providing a standardized encyclopedia of both
somatic and germ line structural genomic variation and thus
aid in deﬁning the relationship of this variation to traits such
as disease.
Other Applications of GW-SNP Assay
It is worth brieﬂy noting a few potential applications of
GW-SNP assay beyond those described above.
The application of this technique for detection of structural
mutation suggests its use in the genomic characterization of
laboratory resources. This could include analysis of human-
derived cell lines that are currently used on a daily basis within
laboratories around the world in addition to the
characterization and monitoring of newly created lines such
as stem cells. Data from our laboratory and others shows both
genomic instability in these lines and the utility of GW-SNP
typing in the molecular characterization of cell lines [19]
(Figure 3); routine monitoring of the genomic variability
within lines will add another layer of quality control and
facilitate more direct comparison between laboratories
working on lines derived from a common founder. With the
release of similar products for other species, it is also expected
that these assays will greatly facilitate the analysis of other
laboratory resources; for example GW-SNP assay would
quickly reveal the extent to which a particular mouse line was
congenic and also allow rapid targeted breeding of animals.
In terms of population-based applications, the density of
these assays and the low mutation rate of SNPs suggest that
these assays will lend themselves to the genetic
characterization of individuals based on genetic background.
The most comprehensive attempt at performing this type of
analysis was previously performed using microsatellite
markers in a panel of approximately 1,064 individuals from
51 distinct populations [20]. While this effort was successful in
anonymously dividing the subjects into their correct
geographic origins, the production of these data was an
enormous undertaking, and it would be difﬁcult to apply
these experiments to a single sample. Some attempt at
deﬁning population-speciﬁc alleles has been performed in
the typing of YRI, CHB, CEU, and JPT subjects; however, GW-
SNP assay of a broader array of populations promises not
only to provide information for admixture analyses but also
insight into genetic drift, relative inbreeding, and genetic
selection across and within populations [3,17].
Conclusions
The ﬁeld of research surrounding GW-SNP assay has taken
enormous leaps forward in the last ﬁve years. The
International HapMap Project has helped to deﬁne
informative genetic variation, and reliable, reproducible
technology capable of leveraging this information is now
realistically available.
In the next period of development it is likely that the
increasing SNP density will begin to level out as the cost/
beneﬁt ratio of increased information content decreases. This
will result in a product that has sufﬁcient coverage to assay
most populations or one that can easily be augmented with
population-speciﬁc SNPs to increase coverage in a particular
population of interest.
The advantages of this method are apparent; it offers
unparalleled density and provides accurate data quickly. The
digital nature of these data means that it is easily transferable
and experiments can be performed in an additive nature
across laboratories. The promise of this method in revealing
the role of common genetic variability in disease is beginning
to be realized, and it is clear that there are many applications
of these data above and beyond simple genetic association.
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